一分钟看懂
这是一项关于急性淋巴细胞白血病的I 期研究，登记的药物或干预包括Anti-CD19/CD22 Dual-Target Cord Blood CAR-T Cells；Fludarabine；Cyclophosphamide，当前状态为招募中。登记地点显示中国上海有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Anti-CD19/CD22 Dual-Target Cord Blood CAR-T Cells；Fludarabine；Cyclophosphamide · I 期
登记条件中文摘要
登记的基本范围为不限性别，年龄18 岁至75 岁；另列出8项专业入选条件，需结合英文原文并由研究团队确认。
登记记录列出8项主要排除条件，具体医学含义需结合英文原文并由研究团队确认。
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Ruijin Hospital, Shanghai Jiao Tong University School of Medicine · 上海
公开的入选条件
- * The patient or their legally authorized guardian has signed the informed consent form (ICF), indicating understanding of the purpose and procedures of this clinical trial and willingness to participate.
- * Age between 18 and 75 years, male or female.
- * Diagnosis of relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) according to the Chinese Guidelines for Diagnosis and Treatment of Adult Acute Lymphoblastic Leukemia (2024 edition).
- * Leukemic cells confirmed to express CD19 and/or CD22 by flow cytometry.
- * ECOG performance status 0-2.
- * Life expectancy ≥12 weeks.
- * Adequate organ function at screening, meeting all of the following laboratory criteria:
- 1. Hematology: absolute neutrophil count (ANC) ≥1×10⁹/L; absolute lymphocyte count (ALC) ≥0.3×10⁹/L; platelet count ≥20×10⁹/L; hemoglobin ≥60 g/L.
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT07838714；登记信息更新于 2026-09-25。